WEKO3
アイテム
{"_buckets": {"deposit": "9cc35462-3b5b-4f63-8d32-e05f9f2dd36e"}, "_deposit": {"created_by": 2, "id": "14342", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "14342"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00014342", "sets": ["9"]}, "author_link": ["52175", "52176", "52174", "52169", "52177", "52168", "52179", "52172", "52171", "52170", "52178", "52173"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2010-10", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "5", "bibliographicPageEnd": "420", "bibliographicPageStart": "418", "bibliographicVolumeNumber": "77", "bibliographic_titles": [{"bibliographic_title": "Joint, bone, spine : revue du rhumatisme"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "OBJECTIVE: The aim of this study was to evaluate whether serum COMP can estimate the therapeutic response of RA after 6 months of treatment with etanercept. METHODS: Forty-five RA patients receiving 25mg of etanercept twice a week for 6 months were registered in this prospective observational study. Clinical response to the therapy was evaluated by DAS 28. Laboratory variables- COMP, CRP, ESR, IgM-RF, MMP-3, and anti-CCP Ab -were assessed at baseline and after 6 months of treatment. We assessed the correlations between serum COMP and other variables and whether serum COMP is associated with DAS28 remission. RESULTS: Serum COMP correlated with DAS28-ESR (p\u003c0.05, r=0.40) at baseline. At 6 months of etanercept treatment, 10 patients entered remission (DAS28-ESR\u003c2.6) whereas the other 35 patients did not (DAS28-ESR\u003e2.6). The decrement of serum COMP at 6 months was significant in the remission group (N=10) but not in the non-remission group (N=35). On the other hand, CRP, ESR and MMP-3 decreased at 6 months regardless of remission status. IgM-RF titer as well as anti-CCP Ab titer did not differ at 6 months. CONCLUSIONS: Serum COMP at baseline reflects clinical disease activity of RA. Serum COMP is a valuable serologic marker to identify the subset of RA patients achieving remission during treatment with etanercept.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Joint Bone Spine, 77(5), pp.418-420; 2010", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier Masson SAS"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "20864374", "subitem_relation_type_select": "PMID"}}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.jbspin.2010.01.016", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright © 2010 Published by Elsevier Masson SAS"}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11698054", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1297319X", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "17787254", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kawashiri, Shin-Ya"}], "nameIdentifiers": [{"nameIdentifier": "52168", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawakami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "52169", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ueki, Yukitaka"}], "nameIdentifiers": [{"nameIdentifier": "52170", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Imazato, Takahiro"}], "nameIdentifiers": [{"nameIdentifier": "52171", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iwamoto, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "52172", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujikawa, Keita"}], "nameIdentifiers": [{"nameIdentifier": "52173", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aramaki, Toshiyuki"}], "nameIdentifiers": [{"nameIdentifier": "52174", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tamai, Mami"}], "nameIdentifiers": [{"nameIdentifier": "52175", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Hideki"}], "nameIdentifiers": [{"nameIdentifier": "52176", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Origuchi, Tomoki"}], "nameIdentifiers": [{"nameIdentifier": "52177", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ida, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "52178", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Eguchi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "52179", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "JBS77_418.pdf", "filesize": [{"value": "547.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 547100.0, "url": {"label": "JBS77_418.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/14342/files/JBS77_418.pdf"}, "version_id": "b466b375-996f-4020-a98e-954f17ce2772"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Cartilage oligomeric matrix protein", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Etanercept", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Rheumatoid arthritis", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab."}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/24324", "pubdate": {"attribute_name": "公開日", "attribute_value": "2010-10-21"}, "publish_date": "2010-10-21", "publish_status": "0", "recid": "14342", "relation": {}, "relation_version_is_last": true, "title": ["Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab."], "weko_shared_id": 2}
Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
http://hdl.handle.net/10069/24324
http://hdl.handle.net/10069/2432499b8a7f1-e94a-4036-adb0-177306be2ad4
名前 / ファイル | ライセンス | アクション |
---|---|---|
JBS77_418.pdf (547.1 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2010-10-21 | |||||
タイトル | ||||||
タイトル | Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Cartilage oligomeric matrix protein | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Etanercept | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Rheumatoid arthritis | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kawashiri, Shin-Ya
× Kawashiri, Shin-Ya× Kawakami, Atsushi× Ueki, Yukitaka× Imazato, Takahiro× Iwamoto, Naoki× Fujikawa, Keita× Aramaki, Toshiyuki× Tamai, Mami× Nakamura, Hideki× Origuchi, Tomoki× Ida, Hiroaki× Eguchi, Katsumi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | OBJECTIVE: The aim of this study was to evaluate whether serum COMP can estimate the therapeutic response of RA after 6 months of treatment with etanercept. METHODS: Forty-five RA patients receiving 25mg of etanercept twice a week for 6 months were registered in this prospective observational study. Clinical response to the therapy was evaluated by DAS 28. Laboratory variables- COMP, CRP, ESR, IgM-RF, MMP-3, and anti-CCP Ab -were assessed at baseline and after 6 months of treatment. We assessed the correlations between serum COMP and other variables and whether serum COMP is associated with DAS28 remission. RESULTS: Serum COMP correlated with DAS28-ESR (p<0.05, r=0.40) at baseline. At 6 months of etanercept treatment, 10 patients entered remission (DAS28-ESR<2.6) whereas the other 35 patients did not (DAS28-ESR>2.6). The decrement of serum COMP at 6 months was significant in the remission group (N=10) but not in the non-remission group (N=35). On the other hand, CRP, ESR and MMP-3 decreased at 6 months regardless of remission status. IgM-RF titer as well as anti-CCP Ab titer did not differ at 6 months. CONCLUSIONS: Serum COMP at baseline reflects clinical disease activity of RA. Serum COMP is a valuable serologic marker to identify the subset of RA patients achieving remission during treatment with etanercept. | |||||
書誌情報 |
Joint, bone, spine : revue du rhumatisme 巻 77, 号 5, p. 418-420, 発行日 2010-10 |
|||||
出版者 | ||||||
出版者 | Elsevier Masson SAS | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1297319X | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 17787254 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA11698054 | |||||
PubMed番号 | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | PMID | |||||
関連識別子 | 20864374 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.jbspin.2010.01.016 | |||||
権利 | ||||||
権利情報 | Copyright © 2010 Published by Elsevier Masson SAS | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Joint Bone Spine, 77(5), pp.418-420; 2010 |